Solid drug delivery apparatus, formulations and methods of use

ABSTRACT

Embodiments provide apparatus and methods for delivering solid form medications such as pellets to various locations in the body. One embodiment provides an apparatus for in vivo delivery of medication pellets comprising a housing including a port, a pellet-containing belt disposed in the housing, and a mechanism for transferring the pellets from the belt to a delivery site (DS) outside the housing. Each pellet contains a dose of drug to treat a medical condition. An elongate member is coupled to the housing and includes a lumen for pellet delivery, a proximal end coupled to the port and a distal end positioned at the DS. The pellet can be delivered to the DS at regular intervals or responsive to a detected biological event. Embodiments of the invention are particularly useful for delivering medication to treat a medical condition over an extended period without requiring a patient to take external medication.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.13/645,344, filed Oct. 4, 2012, which claims benefit of priority to U.S.Provisional Patent Application No. 61/626,909, filed Oct. 4, 2011, theaforementioned priority applications being incorporated herein byreference in their entirety.

This application is also related to U.S. patent application Ser. No.12/661,774, filed Mar. 22, 2010, entitled “Solid Drug Delivery Apparatusand Formulation”; and Ser. No. 12/661,767, filed Mar. 22, 2010, entitled“Methods of Solid Drug Delivery” which are both incorporated byreference herein in their entirety for all purposes.

BACKGROUND OF THE INVENTION Field of the Invention

Embodiments of the invention relate to drug delivery devices and methodsof use thereof. More specifically, embodiments of the invention relateto implantable drug delivery devices for the delivery of solid formdrugs and other therapeutic agents.

The current trend in many medical treatments requires the delivery of adrug to a specific target site so as to avoid the toxicity to othertissue, as well as more precisely controlling the timing and amount ofdrug delivered to that site. In many cases, this can require animplantable drug pump. However, due to their size and power requirementsthe current available pumps do not lend themselves to many medicalapplications, particularly for delivery of medication to the brain,heart and other tissues, where very precisely controlled doses of drugcan be required. Also current devices can require frequent replenishmentof the drug due to limited reservoir size and/or limited shelf life ofthe drug. Thus, there is a need for improved implantable drug deliverydevices and associated methods for in vivo drug delivery.

BRIEF SUMMARY OF THE INVENTION

Embodiments of the invention provide apparatus, systems, formulationsand methods for delivering medications in solid form to variouslocations in the body of a human patient or mammal many embodimentsprovide an implantable apparatus for delivering medication in solid formwherein the medication includes one or more solid form drugs fortreating various medical conditions such as epilepsy and other neuralcondition; diabetes and other endocrine conditions; and cardiacarrhythmias and other cardiac rhythm disorders. Particular embodimentsprovide an enclosed implanted apparatus for delivering solid formmedications such as pellets to a delivery site so as to treat a medicalcondition for an extended period of time. Embodiments also providevarious solid form medications or formulations comprising one or moredrugs to be delivered by embodiments of the apparatus or other drugdelivery apparatus.

One embodiment provides an apparatus for in vivo delivery of solid formmedications or formulations comprising a housing containing: i) one ormore belts including a plurality of doses of medication; and ii) adelivery mechanism for engaging the belt and transferring an individualdose of medication from the belt through a port in the housing wall to aselected tissue delivery site. In many embodiments, the mechanismcomprises an advancement member such as a metal wire and an advancementmeans such as pinch rollers for advancing the advancement member, forexample, by pushing the advancement member. The doses of medication willtypically be individually packaged in packaging containers (e.g., alsoreferred to as packaging) that are integral or otherwise attached to thebelt. The packaging containers are typically sealed and in preferredembodiments, are hermetically sealed. In one embodiment, the packagingcontainer can correspond to sealed foil packaging. According to one ormore embodiments, the advancement member is be configured to push thesolid form medication out of the sealed packaging container and throughthe port in the housing.

According to one or more embodiments the solid form medication isformulated into pellets, though other solid formulations are alsocontemplated (e.g., powder, nanoparticles, etc). Each pellet contains aselected dose of a drug to treat a particular medical condition(s) suchas epilepsy, arrhythmia or diabetes. The dose can be selected based onthe patient's weight, age and particular condition including severity ofthe condition (e.g., moderate vs. severe arrhythmia). Also, themedication pellets are desirably formulated using one or morepharmaceutical excipients, including for example, disintegrants so asdisintegrate and dissolve the pellets in a controlled fashion to achieveand maintain a sufficient concentration of the drug (either at thetissue site, plasma or other tissue location) for treatment of thecondition. The pellets are also desirably fabricated so as to have aproduct life of years or longer in vivo so the drug maintains itspotency and therapeutic effectiveness. The pellets can include aplurality of drugs for treatment of a condition or conditions, forexample, a cocktail of antiviral drugs for treatment of HIV AIDS.

According to one or more embodiments, the belt can configured to holdand dispense a plurality of doses of medication. The belt can be springloaded or use other advancement means. Desirably, the belt contains asufficient supply of medication pellets to provide treatment of thecondition for an extended period of time, for example, two years orlonger.

In many embodiments, an elongate member such as a catheter can becoupled to an opening in the housing. The elongate member has a lumensized to receive the medication pellet, a proximal end coupled to theport or other housing opening and a distal end or tip that extendsthrough an opening in the housing to deliver the pellet to a targettissue site. Desirably, the distal tip has an atraumatic configurationto allow for extended periods of implantation at the target tissue sitewithout a foreign body response such as inflammation, etc. The sameadvancement wire (or other advancement member) which is used to push thepellet out of the packaging container is also used to push or advancethe pellet into the elongate member lumen and out to the target tissuesite.

In many embodiments, the apparatus is coupled to a controller forcontrolling one or more aspects of the medication delivery processincluding, for example, actuation and control of the drive source todeliver a medication pellet. The controller can also be programmed toinclude a delivery regimen wherein medication is delivered at a selectedregular intervals (e.g., once or twice a day, etc.) over an extendedperiod. It can also be configured to receive a signal (e.g., wireless orotherwise) to initiate the delivery of medication or to change thedelivery regimen (e.g., from once a day to twice a day). In this way,the patient or a medical care provider can titrate the delivery ofmedication in response to a specific event (e.g., an episode of anginaor an epileptic pre-seizure event) or to longer term changes in thepatient's condition or diagnosis or both.

According to one or more embodiments, the controller can be operablycoupled to or otherwise receive inputs from an implanted sensor, such asa glucose sensor, which senses a physiologic/biological parameterindicative of a condition to be treated by the medication in the pellet,for example, diabetic hyperglycemia (treated by insulin) or an epilepticseizure (treated by furosemide). When the controller receives an inputfrom the sensor indicative of the condition, it initiates the deliveryof one or more medication pellets to the target tissue site so as totreat the medical condition. Both the initial and subsequent inputs fromthe sensor can be used to titrate the delivery of medication pelletsover an extended period until the condition is dissipated or otherwisetreated. The controller can also receive inputs from other sensorsconfigured to measure the plasma/blood or other tissue concentration ofthe delivered drug. These inputs can also be used to titrate thedelivery of the medication to achieve a selected concentration of drug(e.g., in plasma, tissue, etc.) as well as a selected pharmacokineticprofile. The drug sensors can be positioned at the target tissue site aswell as other sites in the body (e.g., a vein or artery) in order todevelop a pharmacokinetic model of the distribution of the drug atmultiple sites in the body. The apparatus can also include a sensorcoupled to the controller which indicates when the supply of medicationpellets has been exhausted up and/or exactly how many medication pelletsare left. The controller in turn, can signal this information to anexternal communication device such as a cell phone, portable monitor orremote monitor (e.g., at the physician's office). In this way, thepatient and/or medical care provider can take appropriate action wellbefore the apparatus runs out of medication.

The pellets or other solid form of the medication are delivered to adelivery site such as subcutaneous tissue where they are configured tobe broken, disintegrate and absorbed by body tissue fluids so as toproduce a desired concentration of the drug at a target tissue site. Insome applications, the delivery site can be the same as the target site,for example the brain. In other applications, the target site can bedifferent from the delivery site, for example, the delivery site can beintramuscular tissue in the chest and the target site can be the heartor the liver. The delivery site can be adjacent the target site, forexample adipose to deliver to underlying muscle tissue, or it can beplaced at a non-oppositional site, for example, intramuscular deliveryto reach the site of the heart. In each case, the medication pellet caninclude a selected dose of drug and be configured to disintegrate and bedissolved by body tissue fluids so as to yield a therapeuticallyeffective concentration of the drug at the target tissue site. In manyapplications, this involves the pellet being dissolved by body tissuefluids at the delivery site (e.g., interstitial fluids) where the drugthen diffuses from the tissue into the blood stream where it is carriedto the target tissue site. Accordingly, in these and other applications,the dose of the drug in the pellet can be titrated to achieve a selectedplasma (or other tissue compartment) concentration of the drug (orconcentration range) for a selected period during and after dissolutionof the pellet.

In some embodiments, the pellet (including the drug dose) is configuredto disintegrate and be dissolved by the tissue fluids within a bodycompartment such as the cerebrospinal fluid (CSF) in the brain so as toachieve a selected concentration in the tissue fluid within thatcompartment. In particular embodiments for treating various neuraldisorders such as epileptic and other seizures, the pellet is configuredto rapidly disintegrate and be dissolved in the CSF so as to rapidlyachieve a selected concentration of the drug throughout the CSF bathingthe brain to prevent the occurrence of the seizure or lessen itsduration and severity. This can be achieved through the use of one ormore super disintegrants as well as disintegrating enhancing features(e.g., pores, cracks or other intrusions) in or on the pellet. It canalso be achieved by treating the pellet prior to or after delivery withmechanical, electromagnetic, acoustical or other energy to weaken thepellet structure, create cracks and other structural defects for theingress of fluids or initiate the breakup of the pellet into smallerpieces. In other embodiments, a solid form medication for deliverywithin the body of a patient is provided, the medication comprising atleast one drug for the treatment of a disease or condition, wherein themedication has a shape and material properties so as to be: (i) bestored in a container implanted within the body for an extended periodwithout substantial degradation or deleterious effect to the medication,(ii) delivered to a delivery site, and (iii) dissolve in tissue fluidsat the delivery site to produce a therapeutic effect at a target tissuesite to treat the disease or condition.

In various applications, embodiments of the invention can be used todeliver solid form drugs to provide treatment for a number of medicalconditions including epileptic seizures, high blood pressure, elevatedcholesterol, diabetes, coronary arrhythmia's (both atrial andventricular), coronary ischemia (e.g., from a heart attack and/orstenosed coronary artery), cerebral ischemia, stroke, anemia or otherlike condition. The apparatus can be implanted at or near the targettissue site (e.g., the brain) or at remote delivery site (e.g.,subdermally, intramuscularly in the chest or thigh). Further embodimentsof the invention can be used to provide concurrent treatment for two ormore of these or other conditions eliminating the need for the patientto take multiple doses of multiple drugs (e.g., orally or by parenteralmeans) over the course of day. This is particularly beneficial topatients who have long term chronic conditions including those who haveimpaired cognitive abilities.

In an exemplary embodiment of a method for using the invention, theapparatus can be implanted at a selected delivery site (e.g., the brain,or the pectorial region for delivery to the heart) depending on thecondition to be treated. Implantation can be done using an open orminimally invasive surgical procedure known in the art. Prior toimplantation, the apparatus can be loaded with one or more beltsdescribed herein having a selected number of pellets (or other soliddrug formulation) to provide for delivery of pellets to the deliverysite over an extended period of time, e.g., months or years. Onceimplanted, the pellets can be stored in the apparatus for an extendedperiod of time (e.g., 1, 2, 5 years or longer) without degradation ordeleterious effect to the pellets (e.g., loss of drug potency ortherapeutic effectiveness) due to the fact that the pellets are storedin sealed packaging. The apparatus can deliver solid form medication tothe delivery site at regular intervals (e.g., once a day, week, month,etc.) or in response to an input from a sensor. In the latter case, theinput can be indicative of a particular medical condition orbiological/physiological event such as an epileptic seizure orpre-seizure event. A controller described herein can be used todetermine when to initiate delivery based on the sensor input and/or thetime intervals for delivery for embodiments employing delivery atregular intervals. In either case, the controller can send a signal tothe mechanism to deliver a drug pellet from the housing interior to thetissue site. There the drug pellet disintegrates/degrades and isdissolved in local tissue fluids to treat a local target tissue site(e.g., it dissolves in the CSF to treat the brain), or it issubsequently absorbed into the blood stream where it is carried to aremote target tissue site (e.g., the liver, heart, etc.) or both.Further, pellets can be delivered based on input from a sensor providingphysiologic data predictive of the medical condition (e.g., bloodglucose) or another sensor that is configured to sense the local and/orplasma concentration of the drug. In some embodiments, pellet deliverycan be controlled by sensing the state of disintegration of previouslydelivered pellets. For example, another pellet can be delivered when ithas been determined that the previous pellet is in a particular state ofdisintegration (e.g., it has been completely or substantiallydisintegrated). This can be achieved by sending and receiving a signalfrom the pellet such as an optical, ultrasound or electrical signal. Forexample, for the use of optical signal reflectance measurements can beused to determine the state of disintegration. A particulardisintegration state can be determined when the reflectance signal fallsbelow a particular threshold. Similar approaches can be used for use ofreflected ultrasound or impedance. The pellet can even include variousechogenic, or optically opaque or other agents to enhance the reflectedultrasonic, optical or other signal. The pellet may also include variousoptical indicia having one or more of a pattern, size or shapeconfigured to provide an indication of the state of disintegration ofthe pellet.

Further details of these and other embodiments and aspects of theinvention are described more fully below, with reference to the attacheddrawing figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an embodiment of a solid drug delivery apparatus.

FIGS. 1A-1F illustrate use of the apparatus of the embodiment of FIG. 1to deliver a medication pellet or other form of medication to a deliverysite in the body of a patient.

FIGS. 2A and 2B are cross sectional views illustrating an embodiment ofa re-sealable septum having a slit for use with one or more embodimentsof the solid drug delivery apparatus; FIG. 2A shows the septum in theclosed state; and FIG. 2B shows the septum in the open state to allowpassage of a medication pellet.

FIG. 3A is a perspective view showing an embodiment of a belt includinga registration means and a plurality of medication doses contained inpackaging containers that are attached to the belt on an outer surfaceof the packaging container.

FIG. 3B is a side showing of the embodiment of FIG. 3A.

FIG. 4A is a perspective view showing an embodiment of a belt includinga plurality of medication doses contained in packaging containers thatare attached to the belt at a central portion of packaging container.

FIG. 4B is a side showing of the embodiment of FIG. 4A.

FIG. 5 is a perspective viewing showing an embodiment of an individualpackaging container for a dose of solid form medication.

FIG. 6 is a top viewing showing an embodiment of a delivery mechanismincluding a drive source, advancement member, rollers and advancementmember spool.

FIGS. 7A and 7B are side views showing operation of a shape memory metaldrive source for use with a delivery mechanism.

FIG. 8A is a side view illustrating an embodiment of a catheter used todeliver a medication pellet or other solid form of medication to atarget tissue site in the body of a patient.

FIG. 8B is a side view illustrating use of an embodiment of a catheterhaving sensors for measuring the disintegration state of a medicationpellet or other solid form of medication.

FIGS. 9A-9D show embodiments of the apparatus for placement at differentlocations in the body; FIG. 9A shows placement of the entire apparatusin the brain for delivery of medication to a target site in braintissue; FIG. 9B shows placement of the apparatus on the scalp with adelivery catheter extending into brain tissue; FIG. 9C shows anembodiment of the apparatus having two delivery catheters positioned attwo different delivery sites; FIG. 9D shows an embodiment of theapparatus having two delivery catheters with the first delivery catheterpositioned near or in the knee joint and the second delivery catheterpositioned at a different location.

FIG. 10 is a schematic block diagram illustrating an embodiment of acontroller for use with one or more embodiments of the solid drugdelivery apparatus.

FIG. 11A shows placement of a medication pellet in a ventricle of thebrain for dissolution and delivery of medication to a target site in thebrain.

FIG. 11B shows placement of a medication/drug pellet at a delivery sitefor transport of the medication to a target tissue site removed from thedelivery site.

FIGS. 12A and 12B are side views of a medication pellet illustrating thedelivery of force or energy to break down the pellet structure so as toenhance disintegration and dissolution of the pellet in the body; FIG.12A shows the pellet before the delivery of force or energy; and FIG.12B shows the pellet after the delivery of force or energy to createcracks.

FIG. 13 is a side view illustrating the delivery of energy to themedication pellet prior to delivery to enhance dissolution of thepellet.

FIG. 14 is a side view illustrating the delivery of energy to the pelletafter delivery to a delivery site to enhance to dissolution of thepellet.

FIG. 15A is a side view illustrating an embodiment of the medicationpellet.

FIG. 15B is a side view illustrating an embodiment of the medicationpellet having features for accelerating degradation and dissolution ofthe pellet by body tissue fluids.

FIG. 15C is a side view illustrating an embodiment of the medicationpellet having coatings and optical indicia for measurement of pelletdegradation/disintegration by body tissue fluids.

DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the invention provide apparatus, systems, formulationsand methods for delivering medications in solid form to variouslocations in the body. Many embodiments provide an implanted apparatusfor delivering medication in solid form wherein the medication includesone or more solid form drugs or other therapeutic agents for treatingvarious medical conditions such as epilepsy, diabetes, high bloodpressure, and high cholesterol. Particular embodiments provide anenclosed implanted apparatus for delivering solid form medications to adelivery site DS and ultimately to a target tissue site TS (hereintarget site TS), such as the brain or heart, to treat a medicalcondition for an extended period of time. Embodiments also providevarious solid form medications or formulations comprising one or moredrugs to be delivered by embodiments of the apparatus or other soliddrug delivery apparatus.

Referring now to FIGS. 1 and 1A-1F, an embodiment of an apparatus 10 forthe delivery of a solid form medication 100 to a delivery site DS,includes a housing 30 having an interior 31, an interior surface 32 andexterior surface 33 and a port 35. As will be discussed herein, in manyembodiments, port 35 is coupled to an elongate member 60 (also referredto herein sometimes as an elongated member 60) such as a catheter 60having a lumen 61, a proximal end 62 coupled to opening 35 a distal end63 positioned at a tissue delivery site DS for delivery of solidmedication 100 as is shown in the embodiment of FIG. 1. Solid formmedication 100 also described herein as formulation 100, medication 100will typically be formulated into pellets 100, though other solidformulations are also contemplated as is described herein. Medication100 includes one or more drugs or other therapeutic agents 110 to treatone more medical conditions such as various endocrine, cardiovascular orneural conditions.

Housing 30 (also referred to herein as container 30 or chamber 30)contains a drug belt 40 having a plurality of doses 100 d of medication100 and a delivery mechanism 50 (also referred to herein as transfermechanism 50) for engaging belt 40 and transferring an individual dose100 d of medication 100 from the belt through port 35 to deliver it to aselected tissue delivery site DS and a belt drive mechanism or otherbelt advancement means 70 for advancing the belt. Doses 100 d aretypically individual packaged in packaging 41 (also referred to hereinas packaging containers 41) which is integral with or otherwise attachedto belt 40. In some embodiments, multiple doses 100 d (e.g., 2, 3, 4 oreven more doses) of medical 100 may be packaged in an individualpackaging container 41. As will be discussed herein, in manyembodiments, mechanism 50 includes an advancement member 51, such as awire, which is used push dose 100 d out of packaging 41 through port 35,down elongate member 60 and to selected tissue site DS.

In many embodiments, port 35 comprises a sealable septum 36 allowing asolid dose of medication 100 to be passed through the septum bymechanism 50 without the ingress of fluids into housing interior 31 asis shown in the embodiments of FIGS. 2A and 2B. Septum 36 can comprisevarious elastomeric polymers such as silicone or polyurethane which havesufficient resilience to open and then seal itself after being puncturedor otherwise opened by the passage of medication 100 such as amedication pellet 100. In particular embodiments septum 36 can have are-sealable slit 37, that is normally in a closed state (as is shown inFIG. 2A) and is opened by the passage of medication 100 (as is shown inthe embodiment of FIG. 2B) only to close again on itself aftermedication 100 passes through due to the elasticity and resilience ofthe material making up septum 36. In some embodiments apparatus 10 caninclude a first and second septum 36′ and 36″ to reduce the likelihoodof fluid ingress into housing interior 31 during delivery of medication100 as is shown in FIG. 1.

Housing 30 can correspond in size to containers used for variouspacemakers, with larger and smaller sizes contemplated depending uponfor example, the size and configuration of components within the housing(e.g., mechanisms 50, 70 described herein and the desired supply ofmedication 100). It may be fabricated from various biocompatible metalsand plastics known in the art, for example, PET, fluoropolymer, PEBAX,polyurethane, titanium, stainless steel and the like. Also, the interiorsurface 32 or exterior surface 33 of the housing may coated withgas/water vapor impermeable materials or include gas impermeable layers34 so as to minimize the transmission of water vapor into housinginterior 31. Suitable gas/water impermeable materials include isobutylrubbers. Housing 30 can also include one or more biocompatible coatings31C known in the art including polyurethanes, silicones, fluoropolymers,DACRON and the like. Coating 31C can also include various eluting drugssuch as various steroids known in the cardiovascular implant arts forreducing the amount of cellular and other bio-adhesion to the housing.Housing 30 can be sized and shaped to fit in various locations in thebody including: the skull and cranial cavity, the chest, within in oneor more GI organs, the heart, the vascular system, as well as varioussubcutaneous and intramuscular locations including the extremities andthe trunk. All or portions of housing 30 can also be constructed fromconformable materials (e.g., polyurethane silicone and other elastomericpolymers) to conform to the shape of surrounding tissue layers andcompartment, e.g., the curvature on the inside of the skull, or thecontour of the skin. Conforming materials can also be employed to allowfor surrounding body tissue to grow around and reshape the housingduring prolonged periods of implantation. In this way, embodimentshaving a flexible housing minimize the effect of the housing on thegrowth and function of surrounding tissue, thus allowing the apparatusto be implanted over very prolonged periods including allowing theapparatus to be implanted in children and remain through adulthood.Various conformable materials can also be used to facilitateimplantation of apparatus 10 using minimally invasive methods. Suchmaterials allow the apparatus including housing 30 to bend, twist orotherwise conform so as to be inserted through surgical ports andguiding devices and then reassume its shape once positioned at theintended implantation site. In particular embodiments, bending andtwisting of housing 30 can be further facilitated by the use of flexiblejoints built in for the housing. Housing 30 can also be sized and shapedto further facilitate implantation using minimally invasive surgicalmethods. For example, the housing can have a particular size and shapesuch as a cylindrical shape to enable it pass through various minimallyinvasive surgical ports and guiding devices. The housing may also beconfigured to have a collapsed non-deployed state and an expandeddeployed state where the non-deployed state is used for advancing thehousing and the deployed state once the housing is positioned at adesired location in the body.

Referring now to FIGS. 3A-3B and 4A-4B, in various embodiments, belt 40contains a plurality of doses 100 d of solid form medication 100 andalso registration means 45. In many embodiments, registration means 45corresponds to holes 45 h which are used to advance belt 40 by asprocket-based belt advancement means 70 (described herein) as is shownin the embodiment of FIG. 3A. In additional or alternative embodiments,registration means 45 may correspond to: i) optically encoded indicia 45o allowing belt 40 to be advanced by a belt advancement means 70 coupledto an optical sensor 46 (e.g., a photodiode or CCD) for reading opticalindicia 45 o, or ii) electromagnetic indicia 45 e allowing belt 40 to beadvanced by a belt advancement means 70 coupled to an electrical sensor47 (e.g., a conductive contact) for reading electromagnetic indicia 45 eas is shown in the embodiment of FIG. 3B. Still other registration meansare contemplated.

Belt 40 can be fabricated from various metals or polymer films known inthe art such as PET and NYLON. In preferred embodiments, belt 40comprises a stainless steel belt which can be fabricated along withregistration means 45, using various chemical etching methods known inthe art. According to one or more embodiments individual doses 100 d ofmedication 100 (e.g., pellets 100) can be packaged in hermeticallysealed packaging 41 (also referred to herein as packaging containers 41)each packaging container having a body 44 which can be attached to thebelt or otherwise integral to it. In one embodiment shown in FIG. 3A,packaging containers 41 can be attached to belt 40 along a surface 44 sof the packaging container body 44. In another embodiment shown in FIG.4A, packaging containers 41 can be centrally attached or otherwiseintegral to belt 41. Such embodiments can be achieved by fabricatingbelt 40 and packaging containers 41 from the same metal/foil strip orother piece of material (e.g., polymer.).

Typically, packaging container 41 will have a cylindrical shape having abody 44 and first and second ends 42 and 43 as shown in the embodimentof FIG. 5. However, other shapes are also contemplated. Ends 42 and 43are desirably, configured to be puncturable by the advancement ofadvancement member 51, so as to allow the advancement member to pushinto and puncture first end 42 and then push pellet 100 through secondend 43. One or both of ends 42 or 43 can be sealable to body 44 and inpreferred embodiments are hermetically sealed. The ends 42 and 43 mayalso be fabricated from conductive material such that when they arepunctured by advancement member 51, member 51 makes electrical contactcompleting a circuit and sending a signal back to controller 80 to thusprovide an indication that both ends have been punctured. In variousembodiments, packaging containers 41 can comprise various sealable foilsand polymers known in the pharmaceutical packaging arts, for example,PET, HDPE, NYLON and other materials known in the art. In someembodiments, packaging container 41 may have a two-ply or othermulti-ply construction for improved impermeability and shelf life.Packaging containers 41 can be attached to belt 40 using any number ofattachment methods known in the art including for example, adhesivebonding, welding, ultrasonic welding, heat staking or other relatedmethod.

Desirably, belt 40 contains a sufficient supply of medication pellets100 to provide treatment of a particular medical condition for anextended period of time, for example, one to two years, two to fiveyears or longer. Shorter periods are also contemplated. In variousembodiments, belt 40 can hold up to several hundred or more pellets 100.In various embodiments, apparatus 10 can include multiple belts 40,including two, three or more belts. In these and related embodiments,apparatus 10 can include means for switching over from a first to asecond or other belt 40. Such switching means (not shown but readilycomprehendible to those skilled in the electro-mechanical arts) caninclude for example, a solenoid and can be stand alone or incorporatedinto mechanism 50 and/or belt drive mechanism 70 (described herein) forembodiments having the latter.

A discussion will now be presented of delivery mechanism 50 (alsoreferred to sometimes as advancement mechanism 50), herein mechanism 50.In many embodiments, mechanism 50 comprises an advancement member 51coupled to a drive source 52 which may be disposed in a housing (notshown). In particular embodiments, drive source 52 can be used to driveone or both of a set of pinching rollers 53 or other advancement meansas is shown in FIG. 6. Pinch rollers 53 pinch down on advancement member51 to push it out of housing 30 and then withdraw it back into thehousing. Accordingly, in these and related embodiments, drive source 52is configured to move in a linear manner in a forward and then a reversedirection as is shown in the embodiments of FIG. 1A-1F. As is discussedbelow, one or more of the speed, acceleration and direction of the drivesource may be controlled for example, by a controller such as acontroller 80 described herein. Also, in particular embodiments,advancement member 51 is kept in a wound state on a spool 54 (or otherspool means 54) in a retracted position and then unwound when advancedby drive source 52 and rewound when withdrawn back into housing 30.

In various embodiments, advancement member 51 corresponds to a flexiblemetal wire configured to have good pushability (e.g., column strength)and trackability characteristics (as is known in the guide wire arts)when advanced by pinch rollers 53 (or other advancement means known inthe art) through catheter 60 so as to be able to push medication pellet100 out of packaging container 44, through septum or other opening 35,down the length of catheter lumen 61 and out of catheter tip 63 eitherdirectly or out of a slot 63 s. Advancement member 51 is also desirablysufficiently flexible to be wound back up onto spool 54 when theadvancement member is withdrawn back into housing 30. In these andrelated embodiments, advancement member 51 may correspond to a flexiblestainless steel wire (e.g., 304 v wire) or a super elastic wire such asa NITINOL wire. For various metal wire embodiments, advancement member51 may include an inner core for pushability and an outer coil or forenhanced flexibility and trackability. Alternatively, in someembodiments a wire based advancement member 51 may comprise a coiledwire alone having a selectable diameter and pitch to achieve the desiredmechanical properties. Also, all or portions of a wire-based advancementmember 51 may be coated and/or tapered to achieve desired frictional andmechanical characteristics. Coatings can include various lubriciouscoatings known in the art (e.g., TEFLON). Tapering can include both asmooth taper as well steeper tapers to achieve desired transition in themechanical properties of the advancement member. In other embodiments,advancement member 51 may correspond to various resilient polymers knownin the catheter arts. In one variation, all, or a portion, ofadvancement member 51 can itself comprise medication 100 with distalportions of the advancement member advanced through port 35 out ofhousing 30 for delivery to delivery site DS. The advancement member mayinclude fixed length portions 51 p corresponding to a dose 100 d ofmedication 100 as is shown in FIG. 6. Fixed length portions 51 p of amedication containing advancement member 51 may be cut or otherwisebroken off from the body of the advancement member 51 using any numberof cutting means known in the art which built into housing 30 and/ormechanism 50. Separation of fixed length portions 51 p of a medicationcontaining advancement member 51 may also be facilitated by use ofperforations, cracks or other structural defects which are placed intothe length of advancement member 51 during or after fabrication.Medication containing embodiments of advancement member 51 can befabricating using various molding and other shape forming andcompounding methods known in the pharmaceutical manufacturing arts.

As shown in FIG. 6, the length and diameter (including taper for taperedembodiments) of advancement member 51 are desirably configured such thatit can track and move freely within catheter lumen 61 so as to advancemedication pellet 100 out of the catheter 60 (through either tip 63 orslot 63 s described below) to a selected delivery site DS. Additionally,the diameter and shape of the tip 51 t (shown in FIG. 5) of theadvancement member 51 are configured relative to the size of pellet 100such that it can easily push a pellet or other form of medication 100.In some embodiments, advancement member tip 51 t can include a cap 51Cwhich is shaped and sized relative to the shape and size of medicationpellet 100 to improve the ability of advancement member 51 to push thepellet 100 through catheter 60 as is show in FIG. 5. In someembodiments, cap 51C may have a shape which mates or otherwisecomplements the shape of pellet or other form of solid medication 100.

In various embodiments, drive source 52 can correspond to a mechanicaldrive source such as a spring; an electro-mechanical drive source suchas an electric motor, a solenoid or a piezoelectric motor. In preferredembodiments, drive source 52 corresponds to a brushless dc motor or astepper motor which may be controlled by a controller 80 describedherein (or other controller) and is configured to move in a forward andreverse direction. Controller 80 may be used to control the speed,acceleration and direction of drive source so as to control the speed,acceleration and direction of advancement member 51 and in turn that ofmedication pellet 100 or other medication 100. In some embodiments, thespeed of advancement member 51 can be adjusted depending upon theselected delivery site DS. For example, for delicate tissue sites suchas the brain, the speed of the advancement member may be slowed down soas to reduce any potential trauma from medication pellet 100 exitingcatheter 60 (the speed may even be reduced just prior to when the pelletexists the catheter so as not substantially affect delivery time oncecontroller 80 receives a signal to initiate the delivery of medication100). In other cases, the speed of advancement member 51 may beincreased to ensure that pellet 100 completely exists the catheterand/or to even push it a minimum distance away from catheter tip 63 toprevent blockage of the tip and expedite disintegration of themedication pellet 100 at the delivery site DS.

Embodiments of apparatus 10 having an electro-mechanical orthermo-mechanical drive source 52 can also include a battery 55 or otherelectric power source for powering the drive source 52. Suitablebatteries 55 include lithium, lithium-ion, lithium polymer, zinc-air,alkaline and other chemistries known in the electric battery art.Battery 55 may also be selected and configured to be rechargeable.

Referring back to FIG. 1, in various embodiments, belt drive mechanism70 may correspond to a sprocket or other engageable advancement means 71driven by a drive source 72 such as brushless DC motor, stepper motor,or other eletro-mechanical drive means 72. In some embodiments, drivemeans 72 may be one in the same as mechanism 52 with the addition ofvarious gears or other motion control means (e.g., cams, linkages, etc.)for limiting the motion of sprocket 71 to one turn (and thus that ofbelt 40) for a complete advancement and withdrawal of advancement member51 from and to housing 30. In other embodiments, drive source 72 and/orsprocket 71 is linked to drive mechanism 50 by a synchronizing mechanismor element 73, such as a belt, to achieve the desired level ofsynchronization between the motion of sprocket 71/belt 40 andadvancement member 51 as is shown in FIG. 3A. In still otherembodiments, the motion of sprocket 71/belt 40 and advancement member 51can be synchronized electronically using controller 80, for example,using one or more software modules 83 (shown in FIG. 10) contained in amicroprocessor based controller 80 as is described herein. Beltadvancement mechanism or means 70 may also correspond to one or more ofpinch rollers, magnetic, or electrical-based drive means known in theart.

Referring now to FIGS. 7A-7B, in some embodiments, drive source 52 cancomprise a nickel titanium wire (an example including NITINOL) or othershape memory material that changes length in response to heating, forexample from an electrical current which can be supplied by battery 55or other electric power source. In such embodiments, advancement member51 itself may include portions of the thermally extendable shape memorywire.

Referring now to FIG. 8A, in many embodiments, apparatus 10 includes anelongate member 60 attached to housing 30 for delivering a pellet 100 toa target tissue site. Elongate member 60 can comprise a catheter, metalhypo-tube, or other tubular structure known in the catheter andminimally invasive arts. For ease of discussion, member 60 will bereferred to as delivery catheter 60 or catheter 60 but other formsdescribed above are equally applicable. Catheter 60 can be fabricatedfrom various polymeric materials known in the catheter arts including,polyethylene, PET, polyurethanes, silicones, PEBAX and the like. It mayalso be fabricated from various metallic materials including stainlesssteel, and various super-elastic metals shape memory materials such asnickel titanium alloys (an example including NITINOL). Catheter 60 has alumen 61 sized to receive the medication pellet, a proximal end 62positioned inside housing 30 (or coupled to opening 35) and an opendistal end or tip 63 that extends outside of housing 30 to deliver thepellet to a delivery tissue site DS. In some embodiments, distal tip 63may be blocked but include a slot 63 s positioned on the side of thecatheter 60 so as to allow advancement member 51 (or other advancementmeans) to push medication pellet 100 out the side of catheter 60. Invarious embodiments, the outer diameter 60D (see FIG. 1A) of catheter 60can range from 0.5 to 4 mm and the length 601 (see FIG. 1A) from 1 to 10cm with larger and smaller diameter and lengths contemplated. Inparticular embodiments, catheter 60 can have sufficient length todeliver pellet 100 to a different tissue site than the location ofdevice 10 (for example, into the brain when the rest of apparatus 10 islocated outside of the skull).

Also in particular embodiments, catheter 60 can be configured to provideall or a portion of the driving force for advancing pellet 100 fromhousing 30 to delivery site DS. The driving force can comprise aperistaltic like wave of contraction that travels distally along thelength of the catheter. This can be achieved by constructing catheter 60from either a piezoelectric or like material and coupling it to avoltage source or a shape memory material and coupling it to a thermalpower source as is described herein. In the former case, the applicationof a voltage causes contraction of the catheter material and in thelater case, the application of heat does so. In an alternativeembodiment for transporting pellet 100 through catheter 60, pellet 100can be charged or include a charged coating, such that the pellet isrepelled from the catheter by the application of an electric voltage(having an opposite charge) to the catheter surface.

Desirably, distal catheter tip 63 has an atraumatic configuration toallow for extended periods of implantation at the target delivery siteDS. This can be achieved by configuring the tip to have a tapered shape63 t as well as fabricating the tip from one or more atraumatic flexiblepolymeric materials including, for example, silicones polyurethanes,fluoropolymers, hydrogels, polyether block amides (PEBA) and othersknown in the art. Examples of specific atraumatic materials includesilver-hydrogel and PEBAX (a PEBA). Catheter 60 including distal tip 63can also include one or more sensors 64 for making various measurementsat the delivery site DS. Such measurements can include drugconcentration, pH, glucose, various metabolites, tissue PO₂ and CO₂ andthe like.

Referring now to FIG. 8B, in particular embodiments, sensor 64 can alsocomprise sensors 65 for making various measurements for determining thedegradation/disintegration state of pellet 100. Suitable sensors 65 formaking such measurements can comprise optical, impedance, acoustical andchemical sensors. Sensors 65 can also comprise an assembly 66 includingan emitter 66 e and detector 66 d. Assembly 66 can include opticalemitters and detectors for making reflectance measurements andultrasonic transducers (configured as an emitter and detector) formaking ultrasonic measurements. Assembly 66 sends or emits a signal 67which is modulated or otherwise altered by thedegradation/disintegration state of the pellet 100 and then reflectedback by pellet 100 as a signal 68 which can then be analyzed todetermine the degradation state of the pellet. For example, for use ofan optical based assembly 66, signal 67 will be returned as a reflectedsignal 68 which progressively decreases in amplitude as the pellet isdissolved and disintegrated by body tissue fluids. As indicated above,in various embodiments, pellet 100 can include optical indicia 100 c tofacilitate measurement of the degradation state of pellet 100.

Embodiments of apparatus 10 having sensors 65 and/or sensor assembly 66can be used to control or regulate pellet delivery by sensing the stateof disintegration of previously delivered pellets. For example, anotherpellet can be delivered when it has been determined that the previouspellet is in a particular state of disintegration (e.g., it has beencompletely or substantially disintegrated). This determination can beachieved through use of a controller 80 described herein which mayinclude one or more algorithms for analyzing the disintegration state ofthe pellet and using this information to make a delivery decision. Inparticular embodiments, information on the disintegration state of thepellet can be combined with other data for making a pellet deliverydecision with weightings assignable to each group of data. Suchadditional data can include for example, the blood/plasma concentrationof the delivered drug 110 as well as various physiological data (e.g.,temperature, pH, blood gases, etc.) including physiological dataindicative of the medical condition to be treated by the delivered drug110, e.g., blood glucose as an indication of hyperglycemia, EKG as anindication of arrhythmia or brain electrical activity as an indicationof an epileptic seizure or pre seizure event.

Referring now to FIGS. 9A-9D, in various embodiments, the length of thecatheter 60 can be configured to allow the apparatus 10 to be positionednear the delivery site DS or to be positioned at a different location.For example, in one embodiment shown in FIG. 9A, apparatus 10 can bepositioned in the brain B with the catheter tip 63 positioned a shortdistance away. In another embodiment shown in FIG. 9B, the catheter canhave sufficient length to allow distal tip 63 to be positioned in thebrain, while apparatus 10 is placed on the scalp or other locationoutside the skull. In this way, apparatus 10 can be used to delivermedication to a selectable delivery site DS, such as the brain withouthaving to be placed at that site or have any appreciable effect onorgans or tissue at that site other than that of the medication itself.

In some embodiments, apparatus 10 can include multiple catheters 60 soas to allow for the delivery of medication pellets 100 at multiplelocations using a single delivery apparatus 10. For example, in anembodiment shown in FIG. 9C, the distal tip 63 of a first catheter 60′can be placed at first delivery site DS₁ and the distal tip 63 of asecond catheter 60″ can be placed a second delivery site DS₂. In anembodiment shown in FIG. 9D, the first delivery site DS₁ can comprisethe ultimate target site TS such as an arthritic knee joint KJ (or otherarthritic joint) to allow for immediate delivery of medication to thatsite and the second catheter distal tip can be placed at a second siteDS₂ at least partially removed from first site DS₁ such as in muscletissue M or other sub-dermal location to allow for longer termcontrolled release of a drug 110.

Referring now to FIG. 10, in many embodiments, apparatus 10 can includea controller 80 for controlling one or more aspects of the medicationdelivery process including actuation and control of mechanism 50 and/or52. The controller can comprise logic resources 81 such as amicroprocessor, a state device or both; and memory resources 82 such asRAM, DRAM, ROM, etc. Logic resources 81 and/or memory resources 82 mayinclude one or more software modules 83 for operation of the controller80. Through the use of modules 83, the controller 80 may be programmedto include a medication delivery regimen wherein medication is deliveredat regular intervals (e.g., once or twice a day, etc.) over an extendedperiod. The controller may also include an RF device 84 for receiving awireless 85 signal (e.g., wireless or otherwise) to initiate thedelivery of medication or to change the delivery regimen (e.g., fromonce a day to twice a day). In this way, the patient or a medical careprovider can control the delivery of medication in response to aspecific event (e.g., an episode of angina, an abnormal EKG) or longerterm changes in the patient's condition or diagnosis.

The controller 80 can receive inputs 86 from apparatus sensor 64 or aremote sensor 64 r which senses a physiologic parameter indicative of acondition to be treated by the medication pellet 100, e.g., diabetichyperglycemia. When the controller 80 receives an input 86 indicative ofthe condition, it sends a signal 88 to initiate the delivery of one ormore medication pellets 100 to the target tissue site so as to treat themedical condition. Both the initial and subsequent inputs from sensor 64can be used to titrate the delivery of medication pellets over anextended period until the condition is dissipated or otherwise treatedin a selected manner. The controller 80 can also receive inputs 87 fromother sensors 69 which are configured to measure the plasma or othertissue concentration of the delivered drug 110. These inputs 87 can alsobe used to titrate the delivery of the drug to achieve a selectedconcentration of drug. The concentration sensors 69 can be positionedboth at the delivery site DS, the target site TS as well as other sitesin the body (e.g., a vein or artery) in order to develop apharmacokinetic model of the distribution of the drug at multiple sitesin the body.

In various method embodiments of the invention, apparatus 10 is used todeliver pellets or other solid form medication 100 to a selecteddelivery site DS such as subcutaneous tissue where they aredisintegrated and absorbed by body tissue fluids (e.g., interstitialfluids in muscle or dermal tissue) so as to produce a desiredconcentration of drug 110 at a target site TS. Referring now to FIGS.11A and 11B, in some embodiments for use of apparatus 10, the deliverysite DS can be in the same organ and/or compartment as the target siteTS, for example the brain as is shown in the embodiment of FIG. 11A. Inother embodiments, the target site can be different from the deliverysite as is shown in the embodiment of FIG. 11B. For example in oneembodiment, the delivery site can be intramuscular tissue in the chestand the target site can be an organ such as the heart which is removedfrom the delivery site. The delivery site can be oppositional to thetarget site, for example dermal delivery to reach the target site ofunderlying muscle tissue, or it can be placed at a non-oppositionalsite, for example, intramuscular delivery to reach the target site ofthe heart. In each case, the medication pellet 100 can include aselected dose of drug and be configured to disintegrate and be dissolvedby body tissue fluids so as to yield a therapeutically effectiveconcentration of the drug at the target tissue site. In manyapplications, this involves the pellet being dissolved by body tissuefluids at the delivery site (e.g., interstitial fluids) where the drugthen diffuses from the tissue into the blood stream where it is carriedto the target tissue site. Accordingly, in these and other applications,the dose of the drug in the pellet can be titrated to achieve a selectedplasma concentration of the drug (or concentration range) for a selectedperiod during and after dissolution of the pellet.

In some embodiments, pellet 100 is configured to disintegrate and bedissolved by the tissue fluids within a body compartment such as thecerebrospinal fluid (CSF) in the brain so as to achieve a selectedconcentration in the tissue fluid within that compartment as is shown inthe embodiment of FIG. 11A. In particular embodiments for treatingvarious neural disorders such as epileptic and other seizures, pellet100 is configured to rapidly disintegrate and be dissolved incerebrospinal fluid (CSF) so as to rapidly achieve a selectedconcentration of the drug throughout the CSF that bathes the brain inorder to prevent the occurrence of the seizure or lessen its durationand severity. This can be achieved through the use of one or moresuper-disintegrants which are compounded into pellet 100.

Referring now to FIGS. 12-14, in other embodiments, accelerateddisintegration of pellet 100 can also be achieved by treating the pelletprior to, during or after delivery with mechanical, electromagnetic,acoustical or other energy to weaken the pellet structure, create cracksfor the ingress of fluids or initiate the breakup of the pellet intosmaller pieces. As is shown in FIGS. 12A-12B, the delivery of force andenergy can be used to create cracks 105 (or other surface defects) forthe ingress of tissue fluids as well as break the pellet up into smallerpieces 106.

In other embodiments, energy can be delivered to the pellet 100 while itis still in the apparatus 10 to create cracks 105 and weaken the pelletstructure as is shown in the embodiment of FIG. 13. In embodiments whereadvancement member 51 comprises medication 100 itself, energy can bedelivered to create cracks or other structure weakness within discreteportions of the advancement member so as to cause discrete sections 51 pof member 51 to break off (e.g., typically the distal most section)corresponding to a dose 100 d of medication 100 to deliver medication100 to delivery site DS. In one more embodiments, energy delivery can beachieved through use of an acoustical energy device 90 such as anultrasonic transducer with the ultrasonic frequency configured for aresonant frequency of pellet 100. Acoustical or other energy device 90can be coupled to an energy source 91, which can include variouselectrical power sources, and may be the same as battery 55 used topower drive source 72 and/or delivery mechanism 50).

In another embodiment shown in FIG. 14, energy can be delivered to thepellet after it is ejected from catheter 60 and delivered to deliverysite DS. In this embodiment, energy delivery can be achieved through useof an ultrasonic transducer or other energy delivery device 90 placed oncatheter distal tip 63. Ultrasonic transducer 90 emits a beam of energy93 which acts upon pellet 100 to cause cracks 105 and other effects tothe pellet structure to accelerate pellet degradation into pieces 106and disintegration through dissolution by body tissue fluids. Otherforms of energy which can be used to break up and/or weaken thestructure of pellet 100 and accelerate disintegration/degradationinclude optical (e.g., laser), RF, microwave, thermal or other forms ofenergy known in the medical device arts. The energy delivery regimen(e.g., duration, frequency and amount of energy) for weakening thepellet structure (e.g., causing cracks etc.) can be controlled bycontroller 80. The energy delivery regimen can be adjusted dependingupon the size and structure properties of the pellet as well as theparticular delivery site DS. In various embodiments, energy deliverydevice 90 can be powered by power source 55 or have its own powersource.

Referring now to FIG. 15A, as indicated previously solid form medicationalso described herein as medication 100 or formulation 100 willtypically be formulated into pellets 100, though other solidformulations are also contemplated, such as powder, granules and thelike. For ease of discussion, solid form medication 100 will now bereferred to as medication pellets 100 and/or pellets 100, but it will beappreciated that other forms of solid medication 100 are equallyapplicable. Also as used herein, the term medication comprises a drug110 or other therapeutic agent 110 and one or more pharmaceuticalexcipients 120. Other therapeutic agents 110 can include for example,antibodies, vaccines, micro-nutrients and like agents. Accordingly, eachpellet 100 contains a selected dose of a drug or other therapeutic agent110 to treat a particular medical condition such as Furosemide for thetreatment of epilepsy. The dose can be selected based on the patient'sweight and age. Also in many embodiments, the medication pellets 100 canbe formulated using one or more pharmaceutical excipients 120. Suitableexcipients 120 include preservatives for preserving the drug, bindersfor binding the drug components together and disintegrants fordisintegrating and dissolving the pellets in a controlled fashion toachieve and maintain a sufficient concentration of the drug (either atthe tissue site or other tissue location) for treatment of thecondition. As is described herein, disintegrants 120 can includesuper-disintegrants known in the art. Example super-disintegrantsinclude sodium starch glycolate, crospovidone, croscarmellose sodium aswell as related salts and like compounds.

Pellets 100 can have a selectable size and shape 100 s and can compriseany number of drugs or other therapeutic agents and can be fabricatedusing various pharmaceutical manufacturing methods includinglyophilization. In particular embodiments, pellets 100 can have round,oval or other shape. In one or more preferred embodiments, pellet 100has a cylindrical shape so that it can be packaged within individualcompartments 42 of belt 40. The size and shape of pellet 100 can beselected based upon one or more of the required dose of the drug, thedesired disintegration rate and the delivery site. The shape can also beselected for optimized packing into belt 40 or other like element.Particular embodiments of pellets 100 can be shaped and sized to allowfor packing of 50, 100, 200 or more pellets onto belt, 40. The pellets100 are also desirably fabricated so as to have a product life of yearswhen stored in vivo, for example two to five years or longer so that thedrug maintain its potency and therapeutic effectiveness. Such productlives can be achieved through the use of sealed drug compartments 41 aswell as the use of preservatives and lyophilization of one or more ofthe chemical components comprising pellet 100 such that pellets 100including drugs 110 neither substantially degrade nor suffer otherdeleterious effects (e.g., effects which reduce the potency ortherapeutic efficacy of the drug, for example, wherein the potency ortherapeutic efficacy of the drug is reduced by no more than 10, or 1, or0.1%) while stored in compartments 41. Referring back to FIG. 1, shelflives of pellets 100 can also be increased by constructing housing 30 tohave a substantially hermetic seal for example through use ofimpermeable layers 34, to minimize degradation or other deleteriouseffect occurs to pellet 100 from exposure to moisture, air or otherambient condition which may cause degradation of pellet 100. Also, theinterior 31 of housing 30 can include a desiccant such as a Zeolitedesiccant to absorb any water vapor that may get into housing 30. Use ofthe seal for housing 30 alone and/or with a desiccant allows housinginterior 31 to remain substantially isolated from the environment of thebody and thus extend the shelf life of pellets 100.

In various embodiments, pellets 100 can comprise a single or a pluralityof drugs 110. In particular embodiments, pellets 100 can include acombination of drugs for treatment of a single or multiple conditions,for example, a cocktail of antiviral drugs such as protease inhibitorsfor treatment of HIV AIDS and also antibiotics for the treatment ofadjunct bacterial infections.

Referring now to FIGS. 15B and 15C, in various embodiments, pellets 100can include various features and chemical agents to enhance thedegradation/disintegration of the pellet as well as quantify the amountand rate of disintegration (as used herein with respect to pellet 100the terms degrade and disintegrate are essentially interchangeable. Invarious embodiments, the pellet can be porous or and/or include one ormore channels 101 extending inwards from the pellet surface tofacilitate the ingress (through capillary action) of body tissue fluidswithin pellet interior 102 to accelerate disintegration of the pellet bydissolution. In particular embodiments, channels 101 can be arranged ina pattern 103 so as to result in a substantially uniform ingress of bodytissue fluids along the pellet circumference 104 as is show in theembodiment of FIG. 15B.

Referring now to FIG. 15C, in various embodiments, pellets 100 caninclude echogenic, or optically reflective agents 100 a to enhance thereflected an acoustical or optical signal reflected off of pellet 100.As is discussed herein, such signals can be used to quantify the amountof disintegration of pellet 100. The pellet 100 may also include variousoptical indicia 100 c having one or more of a pattern, size or shapeconfigured to provide an indication of the state of disintegration ofthe pellet. The patterns can be configured to enhance reflectance(optical or acoustic), or contrarily to enhance scattering. Multipleindicia having different patterns (e.g., some reflective some causingscattering) can be positioned at several locations on the pellet. Thesize and shape of the indicia 100 c can be used to determine a totalamount of disintegration as well as a rate of disintegration, e.g., thesmaller the size of the indicia the more disintegration has occurredwith the rate of size decrease of the indicia being correlative to arate of disintegration. Various calibration measurements may be made(e.g., measuring pellet mass and indicia size over the time course ofdisintegration) to establish the precise correlative relationshipbetween rate of indicia loss and pellet disintegration (e.g., firstorder, second order, etc.). In particular embodiments, indicia 100 c cancomprise lines, rectangles, or ovals extending over all or a portion ofthe length and width of pellet 100 as is shown in the embodiment of FIG.15C. Other contemplated shapes for indicia 100 i include circles andvarious intersecting shapes such as a crisscross shape. Indicia 100 cmay also be placed at various locations along the perimeter 104 ofpellet 100.

In various applications, embodiments of the invention can be used todeliver pellets 100 or solid form medication to provide treatment for anumber of medical conditions including epileptic seizures (e.g., by useof Furosemide), high blood pressure (e.g., by use of calcium channelblockers, CCBs), elevated cholesterol (e.g., by use of LIPITOR),diabetes (e.g., by use of insulin), coronary arrhythmia's (both atrialand ventricular, e.g., by use of CCB's), coronary ischemia (e.g., by useof nitroglycerin or other vasodilating agent), or cerebral ischemia,heart attack or stroke (e.g., by use of aspirin, TPA or other hemolyticagent), anemia (e.g., by use of ferric-pyrophosphate) or other likeconditions. Further embodiments of the invention can be used to provideconcurrent treatment for two or more of these or other conditionseliminating the need for the patient to take multiple doses of differentdrugs (e.g., orally or by parenteral means) over the course of a day.This is particularly beneficial to patients who have long term chronicconditions including those who have impaired cognitive or physicalabilities.

CONCLUSION

The foregoing description of various embodiments of the invention hasbeen presented for purposes of illustration and description. It is notintended to limit the invention to the precise forms disclosed. Manymodifications, variations and refinements will be apparent topractitioners skilled in the art. For example, embodiments of theapparatus can be sized and otherwise adapted for various pediatric andneonatal applications as well as various veterinary applications (e.g.,for a dog, cat, horse, cow and other mammals).

Elements, characteristics, or acts from one embodiment can be readilyrecombined or substituted with one or more elements, characteristics oracts from other embodiments to form numerous additional embodimentswithin the scope of the invention. Moreover, elements that are shown ordescribed as being combined with other elements, can, in variousembodiments, exist as stand-alone elements. Hence, the scope of thepresent invention is not limited to the specifics of the describedembodiments, but is instead limited solely by the appended claims.

What is claimed is:
 1. A method for delivering solid form medicationwithin a body of a patient, the method comprising: implanting acontainer in the body, wherein said container carries a plurality ofdoses of a solid form medication, each dose being in an individualsealed packaging configured to preserve said doses for an extendedperiod without substantial degradation or deleterious effect to themedication, wherein the medication comprises a drug for the treatment ofa disease or condition; and advancing an advancement member within thecontainer to puncture opposite ends of a single individual sealedpackaging to remove the dose of solid form medication from the sealedpackaging; and continuing to advance the advancement member to deliverthe dose of solid form medication from the container after it has beenremoved from the sealed packaging to a delivery site outside of thecontainer and within the body of the patient so as to produce atherapeutic effect at a target tissue site for the treatment of thedisease or condition.
 2. The method of claim 1, wherein each sealedpackaging comprises a hermetically sealed packaging.
 3. The method ofclaim 1, wherein the plurality of doses of medication are carried by abelt.
 4. The method of claim 3, wherein the belt is advanced with adelivery of each dose of medication to align a next individual sealedpackaging with the advancement member.
 5. The method of claim 1, whereinthe deleterious effect comprises a loss of potency or therapeuticeffectiveness of the drug.
 6. The method of claim 1, further comprising:dissolving the delivered solid form dose of medication at the deliverysite to yield a therapeutically effective amount of the drug at thetarget tissue site.
 7. The method of claim 1, wherein the medicationcomprises a pharmaceutical excipient.
 8. The method of claim 1, whereinthe extended period is up to about five years.
 9. The method of claim 1,wherein the solid form medication is delivered at regular intervals. 10.The method of claim 9, wherein the interval is about an hour, 8 hours,12 hours, 1 day, 2 days or 7 days.
 11. The method of claim 1, whereinthe solid form medication is delivered in response to a sensedphysiological parameter.
 12. The method of claim 11, wherein the sensedphysiological parameter is predictive of a medical condition, aneurological seizure, an epileptic seizure, an arrhythmia, hypertensionor hyperglycemia.
 13. The method of claim 1, wherein the dose ofmedication comprises a drug for the treatment of epilepsy.
 14. Themethod of claim 1, wherein the dose of medication comprises a drug forthe treatment of an arrhythmia.
 15. The method of claim 1, wherein thedose of medication comprises a drug for the treatment of diabetes. 16.The method of claim 1, wherein the dose of medication comprises a drugfor the treatment of angina.
 17. The method of claim 1, furthercomprising implanting the container within the body of the patient. 18.A method for delivering a solid form dose of medication for thetreatment epilepsy, the method comprising: implanting a containeradjacent a skull of a patient, wherein said container carries aplurality of doses of solid form medication in an individual sealedpackaging configured to preserve said doses for an extended periodwithout substantial degradation or deleterious effect to the medication,wherein the medication comprises a drug for the treatment of anepileptic seizure; advancing an advancement member within the containerto puncture opposite ends of a single individual sealed packaging toremove the dose of solid form medication from the sealed packaging; andcontinuing to advance the advancement member to deliver the dose ofsolid form medication from the container after it has been removed fromthe sealed packaging to a delivery site within brain tissue so as toprevent an epileptic seizure or decrease the severity or duration of anepileptic seizure.
 19. The method of claim 18, wherein the drugcomprises furosemide.
 20. The method of claim 18, further comprising:rapidly dissolving the delivered solid form medication within thecerebrospinal fluid (CSF) of the brain to achieve a selectedconcentration of the drug within the CSF to prevent the epilepticseizure or lessen the severity or duration of the epileptic seizure.